DCGI approves a critical drug developed using DRDO technology

16 Mar 2023 • The Defence Ministry announced on Tuesday that the Drug Controller General of India (DCGI) has approved Prussian blue insoluble formulations, a crucial drug developed under the Technology Development Fund for radiological and nuclear emergencies. Two pharma facilities, one in Baddi and the other in Ahmedabad, have been given manufacturing and marketing licences for the commercial use of Prussian blue insoluble formulations developed under the Technology Development Fund (TDF) scheme, the ministry announced. The company developed the drug, known as "prussian blue" insoluble formulations, based on research by Institute of Nuclear Medicine & Allied Sciences (INMAS), Delhi. a lab of Defence Research & Development Organization (DRDO). According to the announcement, the medication will be marketed under the trade names Pru-DecorpTM and PruDecorp-MG. The formulations are intended to clean up Cesium and Thallium, as well as their Active Pharmaceutical Ingredient (API). According to the ministry, it is one of the vital drugs designated by the World Health Organization (WHO) for radiological and nuclear emergencies.

Source: Mint | Read full story

Contact us


+91 9023-729662

Medflix Logo

© 2022 Plexus Professionals Network Pvt Ltd